Orforglipron
A once-daily GLP-1 receptor agonist tablet, approved in the United States in 2026 under the name Foundayo. It holds no EU marketing authorisation.
General information, not medical advice. Docalo does not sell medicines, and prescription-only medicines are prescribed only after an individual medical assessment.
What Orforglipron is and how it works
Orforglipron is a small molecule, not a peptide, that activates the GLP-1 receptor, the same target as the gut hormone that signals fullness after a meal.
The US Food and Drug Administration approved it in April 2026. The European Medicines Agency has not authorised it, so no EU product information exists.
Authorisation status and label
- In the United States it is approved for weight management in adults with obesity, or overweight with a weight-related condition, alongside diet and activity.
- It has no EU authorisation, so no EU label applies to it.
- In the EU it is available only within registered clinical trials.
Only a doctor who knows your history can decide whether a medicine suits you.
How to use Orforglipron
Once a day. In trials it was taken as one tablet a day, without food or water restrictions, with the dose increased in steps every four weeks.
No EU dosing. Without an EU authorisation there is no EU dosing schedule; in the United States the schedule is set by the US label.
Common side effects
Get urgent medical help if (whatever the frequency): Severe, persistent stomach pain, often spreading to the back, Swelling of the face, lips, tongue or throat, or trouble breathing
Most reported in trials (in more than 1 in 10 trial participants): nausea, constipation, diarrhoea, vomiting
Safety
Do not use Orforglipron if
- You are in the EU outside a registered clinical trial, because no EU-authorised product exists
- You already use another GLP-1 receptor agonist
- You are pregnant, planning a pregnancy or breastfeeding
Medicines bought outside the regulated EU supply chain cannot be checked for content or authenticity.
Your questions answered
Is orforglipron authorised in the EU?
What did the main trial study?
More questions
Can orforglipron be obtained in Europe?
References
This page summarises the official product information and the published sources below.
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity (ATTAIN-1) New England Journal of Medicine (PubMed record), 2025
- ATTAIN-1 (NCT05869903) ClinicalTrials.gov, 2025
- Approval letter: Foundayo (orforglipron), NDA 220934 US Food and Drug Administration, 2026
- FDA approves Lilly's Foundayo (orforglipron) Eli Lilly and Company, 2026
- Authorised medicines register European Medicines Agency, 2026
Other medicines used in weight management
Talk to a doctor about weight care
The Docalo membership gives you a doctor's assessment, a personalised plan and monthly follow-up. Your doctor decides what care suits you, with or without medicine.
Talk to a doctor about weight careGeneral information, not medical advice. Docalo does not sell medicines, and prescription-only medicines are prescribed only after an individual medical assessment.
Pay nothing if a doctor doesn't approve your treatment. Every consultation is fully refundable. How refunds work